Study
| Single-arm, multicentre, phase 2 trial |
| Had received at least one line of platinum-based chemotherapy |
| Advanced stage thymoma or thymic carcinoma |
| Avelumab 10 mg/kg/14 day and axitinib 5 mg x 2. (N:32) |
Efficacy
| ORR: 34% (CR: 0, PR: 34%) and SD: 56% |
| mPFS: 7.5 months |
| DOR: 5.5 month |
Safety
| Grade 1 or 2 infusion reactions: 9% |
| Grade ≥3 AEs: Hypertension:19%, CK increase:9% |
| Deaths due to adverse events: No |
Lancet Oncol. 2022 Sep 9;S1470-2045(22)00542-3.
http://doi.org/10.1016/s1470-2045(22)00542-3
Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022
